Vpatch Cardio


Developer of a wearable cardiac arrhythmia detection system combining a 3‑lead adhesive biosensor patch, an on‑body RF transceiver with beat‑by‑beat analysis, and a cellular gateway to a secure cloud patient‑management and reporting platform. The system is designed for multi‑day ambulatory ECG monitoring, automated arrhythmia detection, and real‑time notification to clinicians. The company reports regulatory approvals for major markets and collaboration with external biosensor and biomedical engineering organisations.

Industries

medical-device
wearables

Nr. of Employees

small (1-50)

Vpatch Cardio

Camberwell, Victoria, Australia, Oceania


Patents

Monitoring system

US-8248231-B2

View Details

Products

Wearable disposable 3‑lead ECG biosensor

Single‑use adhesive biosensor array providing diagnostic quality 3‑channel ECG signals for multi‑day wear.

Reusable on‑body RF transceiver (pod)

Small reusable RF transceiver that attaches to the biosensor, performs local beat analysis and forwards events to the cellular gateway.

Cellular gateway device

Pocketable cellular transmitter that forwards encrypted event data over GPRS/cellular networks to the cloud platform.

Cloud reporting and clinician portal

Secure web‑based application for clinician enrolment, patient management, alerting and report generation.


Services

Provision of multi‑day ambulatory ECG monitoring using a disposable adhesive biosensor array and associated reporting.

Real‑time remote monitoring and alerting service that forwards detected cardiac events to clinicians via a secure web portal.

Expertise Areas

  • Ambulatory ECG monitoring
  • Remote patient monitoring / mHealth
  • Arrhythmia detection and clinical diagnostics
  • Biosensor design and materials
  • Show More (4)

Key Technologies

  • Wearable adhesive 3‑lead ECG sensor
  • Embedded microprocessor beat analysis
  • RF transceiver for on‑body communication
  • GPRS/cellular data transmission
  • Show More (4)

News & Updates

Product holds CE‑Mark approval for Europe (stated since 2009).

Included in relevant Australian therapeutic goods listings (stated 2010).

FDA approval for the wearable ECG monitor (stated 2014).

Closed‑loop system reported in use across multiple countries and distributors appointed in USA and Canada.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.